Loading…
Compass Therapeutics, Inc. is projected to rise to $3.63 by 2027, a +56% move from its current price of $2.33. CMPX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $2.27 | $2.33 | $2.39 | +0.04% |
| Jul 13 | $2.25 | $2.33 | $2.42 | +0.08% |
| Jul 14 | $2.23 | $2.33 | $2.44 | +0.12% |
| Jul 15 | $2.21 | $2.33 | $2.46 | +0.16% |
| Jul 16 | $2.20 | $2.33 | $2.48 | +0.20% |
| Jul 17 | $2.19 | $2.34 | $2.49 | +0.24% |
| Jul 18 | $2.18 | $2.34 | $2.51 | +0.28% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.18 | $2.34 | $2.51 | +0.28% |
| Week 2 | $2.12 | $2.34 | $2.59 | +0.56% |
| Week 3 | $2.08 | $2.35 | $2.65 | +0.84% |
| Week 4 | $2.05 | $2.36 | $2.71 | +1.12% |
| Week 5 | $2.02 | $2.36 | $2.77 | +1.40% |
| Week 6 | $1.99 | $2.37 | $2.82 | +1.69% |
| Week 7 | $1.97 | $2.38 | $2.86 | +1.97% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing antibody-based therapeutics for the treatment of various human diseases in the United States. Its work centers on antibody-based approaches with a focus on oncology, and its description includes the development of several antibody programs in addition to its lead candidate.
Its lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. It also develops CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies; and CTX-10726, a bispecific antibody that targets PD-1 and VEGF-A. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
CMPX currently trades at $2.27 with a market cap of $408.8M and a rank of 3137. This places it among smaller-cap healthcare names that are focused on oncology-related therapies. The near-term forecast for CMPX shows a neutral start in 2026, with the average price at $2.27 and a max of $3.13, reflecting a flat close to break-even view in that year.
The forecast moves toward a bullish trajectory in the subsequent years, with 2027 (avg $3.47; max $4.69; ROI 52.9%), 2028 (avg $4.53; max $6.38; ROI 99.7%), and 2030 (avg $5.30; max $7.92; ROI 133.7%). The path continues higher into 2040 (avg $18.92; max $33.24; ROI 733.4%) and 2050 (avg $33.80; max $65.45; ROI 1389.2%), all with bullish sentiment.
A major floor 28.3% below — a decisive break under it would weaken the trend.
The nearest floor, 17.6% below — buyers have tended to step in here.
The nearest ceiling, 3.4% above — a clean break opens room to run.
A major ceiling 180.3% above — clearing it would confirm fresh momentum.
Key CMPX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CMPX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.32 | Buy | $2.30 | Buy |
| MA 10 | $2.25 | Buy | $2.25 | Buy |
| MA 20 | $2.14 | Buy | $2.21 | Buy |
| MA 50 | $2.05 | Buy | $2.54 | Sell |
| MA 100 | $3.72 | Sell | $3.23 | Sell |
| MA 200 | $4.34 | Sell | $3.64 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 57.02 | Neutral |
| Stoch RSI (14) | 93.92 | Sell |
| CCI (20) | 112.71 | Buy |
| Williams %R (14) | -3.12 | Info |
| MACD (12,26,9) | 0.05 | Buy |
| ROC (12) | 13.11 | Buy |
| Bollinger %B (20,2) | 0.88 | Neutral |
| Stochastic %K (14) | 96.88 | Sell |
| TRIX (15) | -0.13 | Sell |
| Awesome (5,34) | 0.18 | Buy |
| Ultimate (7,14,28) | 75.99 | Sell |
| Momentum (10) | 0.26 | Buy |
| Aroon Osc (25) | 72.00 | Buy |
| Hull MA (9) | 2.36 | Sell |
| ADX (14) | 16.15 | Neutral |
| ATR (14) | 0.06 | Info |
The near-term technical picture is bullish, with an RSI(14) of 50 and moving averages tracking the price. The SMA50 sits at $2.20 while the SMA200 sits at $4.37, indicating a near-term basis that could resist aggressive upside moves. Support is indicated at $1.89 and resistance at $2.41, providing a defined trading range around the current level.
The 30-day range spans from a low of $1.85 to a high of $2.78, outlining the immediate volatility band to watch.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.67 | $2.33 | $3.23 | 0% | Neutral | |
| $2.90 | $3.63 | $4.81 | +56% | Bullish | |
| $3.67 | $4.73 | $6.50 | +103% | Bullish | |
| $3.98 | $5.25 | $7.42 | +125% | Bullish | |
| $4.40 | $5.91 | $8.55 | +153% | Bullish | |
| $4.86 | $6.65 | $9.82 | +185% | Bullish | |
| $5.72 | $7.96 | $11.98 | +241% | Bullish | |
| $7.09 | $10.02 | $15.35 | +330% | Bullish | |
| $7.97 | $11.43 | $17.77 | +390% | Bullish | |
| $9.02 | $13.13 | $20.72 | +464% | Bullish | |
| $14.83 | $23.02 | $38.60 | +888% | Bullish | |
| $25.64 | $44.50 | $81.52 | +18.1x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $1.67 | $2.33 | $2.84 | +0.00% |
| August 2026 | $2.08 | $2.46 | $2.97 | +5.42% |
| September 2026 | $2.03 | $2.42 | $2.96 | -1.63% |
| October 2026 | $2.00 | $2.39 | $2.95 | -1.02% |
| November 2026 | $2.08 | $2.49 | $3.11 | +4.31% |
| December 2026 | $2.14 | $2.58 | $3.23 | +3.38% |
Click any year to see its month-by-month CMPX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect CMPX to range from $1.67 to $3.23 through 2026. The $2.33 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The CMPX price prediction for 2027 points to an average of $3.63 (low $2.90, high $4.81) — a potential gain of +56% on today's $2.33. Momentum favours further upside here.
In 2028, CMPX is projected to trade between $3.67 and $6.50, averaging $4.73 — a potential gain of +103% from today's $2.33. That is up +30% on the projected 2027 average. Buyers look set to stay in control over this stretch.
Compass Therapeutics, Inc.'s 2029 outlook centres on $5.25, within a $3.98 to $7.42 range. That is up +11% on the projected 2028 average. That marks a +125% change versus current levels. Momentum favours further upside here.
By 2030, CMPX could reach as high as $8.55, with a base case around $5.91 and support toward $4.40 — roughly +153% from $2.33. Buyers look set to stay in control over this stretch.
Expect CMPX to range from $4.86 to $9.82 through 2031. The $6.65 average target implies a +185% move from current prices. That is up +13% on the projected 2030 average. Momentum favours further upside here.
The CMPX price prediction for 2032 points to an average of $7.96 (low $5.72, high $11.98) — a potential gain of +241% on today's $2.33. Buyers look set to stay in control over this stretch.
In 2033, CMPX is projected to trade between $7.09 and $15.35, averaging $10.02 — a potential gain of +330% from today's $2.33. That is up +26% on the projected 2032 average. Momentum favours further upside here.
Compass Therapeutics, Inc.'s 2034 outlook centres on $11.43, within a $7.97 to $17.77 range. That is up +14% on the projected 2033 average. That marks a +390% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, CMPX could reach as high as $20.72, with a base case around $13.13 and support toward $9.02 — roughly +464% from $2.33. Momentum favours further upside here.
Expect CMPX to range from $14.83 to $38.60 through 2040. The $23.02 average target implies a +888% move from current prices. That is up +75% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The CMPX price prediction for 2050 points to an average of $44.50 (low $25.64, high $81.52) — a potential gain of +18.1x on today's $2.33. Momentum favours further upside here.
Investing $1,000 in CMPX today (≈ 429.184549 CMPX) could be worth
$19,099.95
+$18,099.95 (+1810%) by 2050 · US Dollar
Based on the average projected CMPX price of $44.5 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CMPXwould be worth at today's price.
$1,000 invested in CMPX on Jul 10, 2025 (≈ 350.877205 CMPX) would be worth
$817.54
-$182.46 (-18.2%) today · 0.82× · US Dollar
Based on a CMPX entry price of $2.85 vs. today's $2.33.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.27 | $1,026.43 | +2.6% |
| 1 month ago | $1.92 | $1,213.54 | +21.4% |
| 3 months ago | $5.17 | $450.68 | -54.9% |
| 6 months ago | $5.21 | $447.22 | -55.3% |
| 1 year ago | $2.85 | $817.54 | -18.2% |
| All time (5.0y) ago | $5 | $466 | -53.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CMPX forecast.
Our base-case forecast reaches $4.70 around 2028.
Implied market cap at $4.70: $846.41M
The multi-year forecast shows a clear uptrend in average prices and rising potential returns from 2026 through 2050. The 2030 forecast yields an average price of $5.30 with an ROI of 133.7%, and the sentiment is bullish for that horizon. This suggests meaningful upside relative to today’s price if the assumptions play out.
By 2040, the average forecast climbs to $18.92 with an ROI of 733.4%, maintaining a bullish stance. The long-range view extends to 2050, where the average is $33.80 and the ROI rises to 1389.2%, again with bullish sentiment. These figures illustrate substantial upside potential over the longer term, balanced by the general biotech risk profile and execution uncertainty.
These figures are estimates and not guarantees. They reflect expected price paths under the stated assumptions and carry substantial uncertainty and risk, as is typical for biotechnology equities with clinical-stage programs.
Tap a question to reveal the answer.
2030 avg $5.30; min $3.84; max $7.92; ROI 133.7%; sentiment BULLISH.
Forecasts show upside potential across multiple years, with 2027 avg $3.47, 2028 avg $4.53, 2040 avg $18.92, and 2050 avg $33.80, with ROIs up to 1389.2% and bullish sentiment in later years.
Yes. The 2032 forecast shows a max of $10.58, with 2032 avg $6.78 and min $4.71; ROI 198.7% and sentiment BULLISH.
Current price is $2.27. For 2026, min $1.67, avg $2.27, max $3.13; ROI 0%; sentiment NEUTRAL.
The 30-day range is $1.85 to $2.78. RSI(14) is 50; SMA50 is $2.20; SMA200 is $4.37. Support is $1.89 and resistance is $2.41.
Compass Therapeutics, Inc. Community Discussion
0Share your Compass Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.